A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane.

Trial Profile

A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Everolimus (Primary) ; Exemestane (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms 4EVER
  • Sponsors Novartis
  • Most Recent Events

    • 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Dec 2013 Results of an analysis on bone turnover markers presented at the 36th Annual San Antonio Breast Cancer Symposium.
    • 21 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top